Bucciarelli-Ducci Chiara, Bianchi Maria, De Luca Leonardo, Battagliese Alessandro, Di Russo Cristian, Proietti Paola, Vizza Carmine D, Fedele Francesco
Department of Cardiovascular and Respiratory Sciences, Policlinico Umberto I, University of Rome La Sapienza, Rome, Italy.
Am J Cardiol. 2006 Nov 15;98(10):1349-53. doi: 10.1016/j.amjcard.2006.06.025. Epub 2006 Sep 26.
The role of glucose-insulin-potassium (GIK) infusion in the management of acute coronary syndrome is controversial. Limited data are available on the effects of adjunctive high-dose GIK (30% glucose, 50 IU of insulin, 80 mEq of potassium chloride infused at 1.5 ml/kg/hour over 24 hours) on myocardial perfusion and left ventricular (LV) remodeling in patients treated with primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction. In this prospective study, 73 patients were randomized to receive GIK infusion (n = 40) or saline (placebo, n = 33) in addition to standard therapy. The primary end points were myocardial perfusion after PCI and LV remodeling at 6 months. Thrombolysis In Myocardial Infarction frame count and myocardial blush grade were evaluated before and after reperfusion treatment. LV end-diastolic and end-systolic volumes, ejection fraction, and wall motion score index were assessed in each patient after PCI and after 6 months. Although no differences in final Thrombolysis In Myocardial Infarction flow were observed between the 2 groups, myocardial blush grade 3 was more frequently achieved in the GIK group (p <0.05). At 6 months, ventricular remodeling was more often observed in the control group (24% vs 3%, p <0.05). In conclusion, GIK infusion in adjunct to primary PCI in patients with ST-segment elevation myocardial infarction was safe, improved myocardial perfusion after revascularization, and was associated with less LV remodeling at follow-up.
葡萄糖 - 胰岛素 - 钾(GIK)输注在急性冠脉综合征管理中的作用存在争议。关于辅助大剂量GIK(30%葡萄糖、50国际单位胰岛素、80毫当量氯化钾,以1.5毫升/千克/小时的速度在24小时内输注)对接受直接经皮冠状动脉介入治疗(PCI)的ST段抬高型心肌梗死患者心肌灌注和左心室(LV)重塑的影响,现有数据有限。在这项前瞻性研究中,73例患者被随机分组,除标准治疗外,分别接受GIK输注(n = 40)或生理盐水(安慰剂,n = 33)。主要终点为PCI后的心肌灌注和6个月时的LV重塑。在再灌注治疗前后评估心肌梗死溶栓帧数和心肌 blush 分级。在PCI后和6个月后评估每位患者的LV舒张末期和收缩末期容积、射血分数和壁运动评分指数。尽管两组之间最终的心肌梗死溶栓血流无差异,但GIK组更频繁地达到心肌 blush 分级3级(p <0.05)。在6个月时,对照组更常观察到心室重塑(24%对3%,p <0.05)。总之,ST段抬高型心肌梗死患者在直接PCI基础上加用GIK输注是安全的,可改善血运重建后的心肌灌注,且随访时LV重塑较少。